Contract Research Organizations (CROs) have evolved from simple service providers to key strategic partners in drug discovery. Initially, pharmaceutical companies outsourced limited tasks to reduce costs, but today, they collaborate with CROs throughout the entire drug discovery process, from ideation to early clinical trials. This shift reflects Big Pharma’s growing confidence in CROs’ expertise and ability to manage intellectual property securely.

In tune with this trend, the CRO market is expanding rapidly and is expected to grow to $6.3 billion by 2030. The focus is on high-value therapeutic areas like oncology, cardiovascular diseases, and anti-infectives. Small and medium-sized biotechs, in particular, rely on CROs for end-to-end capabilities, enabling them to compete effectively despite limited resources.

With increasing demand, CROs are enhancing their expertise in cutting-edge fields such as cell and gene therapies, immunotherapies, and mRNA-based treatments. The rise of digitization is also shaping the selection criteria for outsourcing partners.

Leading CRO-CDMO Syngene, headquartered in India, can be a trusted partner, given its end-to-end solutions across small molecules and biologics, process efficiency, manufacturing capacity, robust supply chain, and more.